Algert Global LLC Has $1.12 Million Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Algert Global LLC boosted its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 175.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 49,197 shares of the life sciences company's stock after purchasing an additional 31,317 shares during the period. Algert Global LLC owned about 0.06% of Integra LifeSciences worth $1,116,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Quadrant Capital Group LLC raised its stake in shares of Integra LifeSciences by 5,960.9% in the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after acquiring an additional 1,371 shares during the last quarter. Sterling Capital Management LLC increased its holdings in Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock valued at $49,000 after purchasing an additional 1,931 shares in the last quarter. Nisa Investment Advisors LLC raised its position in Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after purchasing an additional 2,800 shares during the last quarter. Covestor Ltd boosted its stake in Integra LifeSciences by 61.8% in the fourth quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after purchasing an additional 2,071 shares in the last quarter. Finally, Empowered Funds LLC bought a new stake in shares of Integra LifeSciences during the fourth quarter worth $180,000. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Trading Down 4.4%

Shares of NASDAQ:IART traded down $0.59 during trading on Wednesday, hitting $12.92. 1,505,170 shares of the company's stock were exchanged, compared to its average volume of 1,047,045. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. The firm has a market cap of $1.00 billion, a P/E ratio of -143.54, a PEG ratio of 0.73 and a beta of 1.27. The firm has a 50-day moving average price of $18.59 and a two-hundred day moving average price of $21.81. Integra LifeSciences Holdings Co. has a 1-year low of $11.60 and a 1-year high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The business had revenue of $382.65 million for the quarter, compared to analyst estimates of $381.17 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences's revenue was up 3.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.55 EPS. Equities analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on IART shares. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Truist Financial dropped their target price on shares of Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research note on Friday, April 11th. JPMorgan Chase & Co. decreased their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Wells Fargo & Company lowered their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Finally, JMP Securities dropped their price objective on shares of Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Four investment analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $18.63.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.